Anti-B3AT/ SLC4A1/ AE1 monoclonal antibody
Anti-B3AT/ SLC4A1/ AE1 antibody for FACS & in-vivo assay
Go to SLC4A1/SLC4A1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP1634-Ab-1/ GM-Tg-hg-MP1634-Ab-2 | Anti-Human SLC4A1 monoclonal antibody | Human |
GM-Tg-rg-MP1634-Ab-1/ GM-Tg-rg-MP1634-Ab-2 | Anti-Rat SLC4A1 monoclonal antibody | Rat |
GM-Tg-mg-MP1634-Ab-1/ GM-Tg-mg-MP1634-Ab-2 | Anti-Mouse SLC4A1 monoclonal antibody | Mouse |
GM-Tg-cynog-MP1634-Ab-1/ GM-Tg-cynog-MP1634-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SLC4A1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP1634-Ab-1/ GM-Tg-felg-MP1634-Ab-2 | Anti-Feline SLC4A1 monoclonal antibody | Feline |
GM-Tg-cang-MP1634-Ab-1/ GM-Tg-cang-MP1634-Ab-2 | Anti-Canine SLC4A1 monoclonal antibody | Canine |
GM-Tg-bovg-MP1634-Ab-1/ GM-Tg-bovg-MP1634-Ab-2 | Anti-Bovine SLC4A1 monoclonal antibody | Bovine |
GM-Tg-equg-MP1634-Ab-1/ GM-Tg-equg-MP1634-Ab-2 | Anti-Equine SLC4A1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP1634-Ab-1/ GM-Tg-hg-MP1634-Ab-2; GM-Tg-rg-MP1634-Ab-1/ GM-Tg-rg-MP1634-Ab-2; GM-Tg-mg-MP1634-Ab-1/ GM-Tg-mg-MP1634-Ab-2; GM-Tg-cynog-MP1634-Ab-1/ GM-Tg-cynog-MP1634-Ab-2; GM-Tg-felg-MP1634-Ab-1/ GM-Tg-felg-MP1634-Ab-2; GM-Tg-cang-MP1634-Ab-1/ GM-Tg-cang-MP1634-Ab-2; GM-Tg-bovg-MP1634-Ab-1/ GM-Tg-bovg-MP1634-Ab-2; GM-Tg-equg-MP1634-Ab-1/ GM-Tg-equg-MP1634-Ab-2 |
Products Name | Anti-SLC4A1 monoclonal antibody |
Format | mab |
Target Name | SLC4A1 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-SLC4A1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species B3AT/ SLC4A1/ AE1 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP1634 |
Target Name | SLC4A1 |
Gene ID | 6521,20533,24779,100427618,490939,101099413,286817,100009691 |
Gene Symbol and Synonyms | AE1,BB3,BND3,CD233,CHC,DI,EMPB3,EPB3,FR,l11Jus51,RTA1A,SAO,SLC4A1,SPH4,SW,WD,WD1,WR |
Uniprot Accession | P02730,P23562 |
Uniprot Entry Name | B3AT_HUMAN,B3AT_RAT |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000004939 |
Target Classification | N/A |
The target: SLC4A1, gene name: SLC4A1, also named as AE1, BND3, CD233, CHC, DI, EMPB3, EPB3, FR, RTA1A, SAO, SPH4, SW, WD, WD1, WR. The protein encoded by this gene is part of the anion exchanger (AE) family and is expressed in the erythrocyte plasma membrane, where it functions as a chloride/bicarbonate exchanger involved in carbon dioxide transport from tissues to lungs. The protein comprises two domains that are structurally and functionally distinct. The N-terminal 40kDa domain is located in the cytoplasm and acts as an attachment site for the red cell skeleton by binding ankyrin. The glycosylated C-terminal membrane-associated domain contains 12-14 membrane spanning segments and carries out the stilbene disulphonate-sensitive exchange transport of anions. The cytoplasmic tail at the extreme C-terminus of the membrane domain binds carbonic anhydrase II. The encoded protein associates with the red cell membrane protein glycophorin A and this association promotes the correct folding and translocation of the exchanger. This protein is predominantly dimeric but forms tetramers in the presence of ankyrin. Many mutations in this gene are known in man, and these mutations can lead to two types of disease: destabilization of red cell membrane leading to hereditary spherocytosis, and defective kidney acid secretion leading to distal renal tubular acidosis. Other mutations that do not give rise to disease result in novel blood group antigens, which form the Diego blood group system. Southeast Asian ovalocytosis (SAO, Melanesian ovalocytosis) results from the heterozygous presence of a deletion in the encoded protein and is common in areas where Plasmodium falciparum malaria is endemic. One null mutation in this gene is known, resulting in very severe anemia and nephrocalcinosis. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.